DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pyo, Ayoung | ko |
dc.contributor.author | Yun, Misun | ko |
dc.contributor.author | Kim, Hyeon Sik | ko |
dc.contributor.author | Kim, Tae Yoon | ko |
dc.contributor.author | Lee, Joong-Jae | ko |
dc.contributor.author | Kim, Jung Young | ko |
dc.contributor.author | Lee, Sunwoo | ko |
dc.contributor.author | Kwon, Seong Young | ko |
dc.contributor.author | Bom, Hee-Seung | ko |
dc.contributor.author | Kim, Hak-Sung | ko |
dc.contributor.author | Kim, Dong-Yeon | ko |
dc.contributor.author | Min, Jung-Joon | ko |
dc.date.accessioned | 2018-02-21T06:39:02Z | - |
dc.date.available | 2018-02-21T06:39:02Z | - |
dc.date.created | 2018-02-19 | - |
dc.date.created | 2018-02-19 | - |
dc.date.created | 2018-02-19 | - |
dc.date.created | 2018-02-19 | - |
dc.date.created | 2018-02-19 | - |
dc.date.issued | 2018-02 | - |
dc.identifier.citation | JOURNAL OF NUCLEAR MEDICINE, v.59, no.2, pp.340 - 346 | - |
dc.identifier.issn | 0161-5505 | - |
dc.identifier.uri | http://hdl.handle.net/10203/240384 | - |
dc.description.abstract | The epidermal growth factor receptor (EGFR) is a member of the erbB family of receptors and is overexpressed in many tumor types. A repebody is a newly designed nonantibody protein scaffold for tumor targeting that contains leucine-rich repeat modules. In this study, 3 Cu-64-labeled anti-EGFR repebodies with different chelators were synthesized, and their biologic characteristics were assessed in cultured cells and tumor-bearing mice. Methods: Repebodies were synthesized with the chelators 2-(p-isothiocyanatobenzyl)1,4,7-triazacyclononane-N, N',N,"-triacetic acid trihydrochloride ([p-SCN-Bn]-NOTA), 2,2',2 ''-(10-(2-(2,5-dioxopyrrolidin-1-yloxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid (DOTA-N-hydroxysuccinimide ester), or 1-(p-isothiocyanatobenzyl) diethylenetriamine pentaacetic acid trihydrochloride ([p-SCN-Bn]DTPA) in 1.0 M NaHCO3 buffer (pH 9.2) for 24 h. Purified NOTA-, DOTA-, and DTPA-conjugated repebody were radiolabeled with Cu-64 in 0.1 M NH4OAc buffer (pH 5.5). To compare the EGFR-binding affinities of the repebodies, cellular uptake studies were performed with the human non-small cell lung cancer cell line H1650 (high expression of EGFR) and the human colon adenocarcinoma cell line SW620 (low expression of EGFR). Biodistribution and small-animal PET imaging studies were performed using H1650 tumor-bearing mice. Results: Radiochemical yields of the Cu-64-labeled repebodies were approximately 70%-80%. Cellular uptake of the NOTA-, DOTA-, and DTPA-repebodies was over 4-fold higher in H1650 cells than in SW620 cells at 1 h. The 3 repebodies had accumulated specifically in H1650 tumor-bearing nude mice by 1 h after intravenous injection and were retained for over 24 h, as measured by the percentage injected dose per gram of tissue (% ID/g). Tumor uptake of all repebodies increased from 1 to 6 h (at 1 h, 6.28, 8.46, and 6.91 % ID/g for NOTA-, DOTA-, and DTPA-repebody, respectively; at 6 h, 9.4, 8.28, and 10.1 % ID/g, respectively). H1650 tumors were clearly visible after injection of each repebody, with high tumor-to-background ratios (at 1 h, 3.43, 4.89, and 2.38 for NOTA-, DOTA-, and DTPA-repebody, respectively; at 6 h, 3.05, 4.36, and 2.08; at 24 h, 3.81, 4.58, and 2.86). Conclusion: The 3 Cu-64-repebody complexes demonstrated specific and rapid uptake in EGFR-expressing tumors within 1 h and may have potential as novel EGFR imaging agents for PET. | - |
dc.language | English | - |
dc.publisher | SOC NUCLEAR MEDICINE INC | - |
dc.title | Cu-64-Labeled Repebody Molecules for Imaging of Epidermal Growth Factor Receptor-Expressing Tumors | - |
dc.type | Article | - |
dc.identifier.wosid | 000423848200029 | - |
dc.identifier.scopusid | 2-s2.0-85041413650 | - |
dc.type.rims | ART | - |
dc.citation.volume | 59 | - |
dc.citation.issue | 2 | - |
dc.citation.beginningpage | 340 | - |
dc.citation.endingpage | 346 | - |
dc.citation.publicationname | JOURNAL OF NUCLEAR MEDICINE | - |
dc.identifier.doi | 10.2967/jnumed.117.197020 | - |
dc.contributor.localauthor | Kim, Hak-Sung | - |
dc.contributor.nonIdAuthor | Pyo, Ayoung | - |
dc.contributor.nonIdAuthor | Yun, Misun | - |
dc.contributor.nonIdAuthor | Kim, Hyeon Sik | - |
dc.contributor.nonIdAuthor | Kim, Jung Young | - |
dc.contributor.nonIdAuthor | Lee, Sunwoo | - |
dc.contributor.nonIdAuthor | Kwon, Seong Young | - |
dc.contributor.nonIdAuthor | Bom, Hee-Seung | - |
dc.contributor.nonIdAuthor | Kim, Dong-Yeon | - |
dc.contributor.nonIdAuthor | Min, Jung-Joon | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | repebody | - |
dc.subject.keywordAuthor | positron emission tomography | - |
dc.subject.keywordAuthor | molecular imaging | - |
dc.subject.keywordAuthor | Cu-64 labeling | - |
dc.subject.keywordAuthor | EGFR | - |
dc.subject.keywordPlus | CANCER CELL-LINES | - |
dc.subject.keywordPlus | EGFR EXPRESSION | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | CARCINOMA MODEL | - |
dc.subject.keywordPlus | PET | - |
dc.subject.keywordPlus | ANTIBODY | - |
dc.subject.keywordPlus | BINDING | - |
dc.subject.keywordPlus | RADIOIMMUNOTHERAPY | - |
dc.subject.keywordPlus | OVEREXPRESSION | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.